PEEL-224

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NamePEEL-224
Drug Alias NamePEG [SN22]4Polymer based prodrug of SN22 (PEEL Therapeutics)PEEL-224
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursNeuroblastomaDesmoplastic Small Round Cell Tumor +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPeel Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPeel Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeuroblastomaDesmoplastic Small Round Cell Tumor +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A